Project Grant R34HL186380

The National Heart, Lung, and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $161,500 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support planning activities for a future multisite cluster randomized trial on hypertensive disorders of pregnancy prevention in safety-net clinics.

The award funds a preparation phase to evaluate the feasibility and acceptability of implementation intervention components designed to improve guideline-concordant care for preventing preeclampsia. The recipient will engage 10–15 safety-net clinics across Los Angeles County to assess preeclampsia burden, current practices, and readiness for research collaboration; conduct qualitative interviews with 50 patients and clinicians to identify implementation barriers and assess current hypertensive disorder of pregnancy prevention efforts; and map candidate implementation interventions. The work addresses persistent under-prescribing of low-dose aspirin (81 mg daily) for high-risk pregnancies despite strong evidence and national guidelines, particularly in resource-constrained settings where hypertensive disorder of pregnancy risk is highest.

Performance takes place in Torrance, California. The period of performance runs through June 30, 2029. The award is classified as a Project Grant, an assistance type supporting investigator-initiated research projects.